MASSBIOLOGICS
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1894-01-01
- Employees
- 251
- Market Cap
- -
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People
- Conditions
- Lyme Disease
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- MassBiologics
- Target Recruit Count
- 44
- Registration Number
- NCT04863287
- Locations
- 🇺🇸
Celerion Inc., Lincoln, Nebraska, United States
Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- MassBiologics
- Target Recruit Count
- 41
- Registration Number
- NCT04075175
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
- Conditions
- Hepatitis C Infection
- Interventions
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- MassBiologics
- Target Recruit Count
- 11
- Registration Number
- NCT01532908
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C
- Conditions
- HCV InfectionLiver Transplantation
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- MassBiologics
- Target Recruit Count
- 13
- Registration Number
- NCT01121185
- Locations
- 🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C
- Conditions
- Healthy
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- MassBiologics
- Target Recruit Count
- 31
- Registration Number
- NCT00952263
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
- Prev
- 1
- 2
- Next
News
Lyme PrEP: Novel Monoclonal Antibody Treatment Enters Human Clinical Trials
MassBiologics of UMass Medical School has initiated the first human clinical trial of Lyme PrEP, a pre-exposure prophylaxis using a single monoclonal antibody that could prevent Lyme disease.